Cite
Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
MLA
Cheng, Pin‐Nan, et al. “Body Weight Increase and Metabolic Derangements after Tenofovir Disoproxil Fumarate Switch to Tenofovir Alafenamide in Patients with Chronic Hepatitis B.” Alimentary Pharmacology & Therapeutics, vol. 59, no. 2, Jan. 2024, pp. 230–38. EBSCOhost, https://doi.org/10.1111/apt.17765.
APA
Cheng, P., Feng, I., Chen, J., Kuo, H., Lee, P., Yu, M., Chiu, Y., Chiu, H., Chien, S., Chen, P., & Liu, C. (2024). Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics, 59(2), 230–238. https://doi.org/10.1111/apt.17765
Chicago
Cheng, Pin‐Nan, I‐Cher Feng, Jyh‐Jou Chen, Hsing‐Tao Kuo, Pei‐Lun Lee, Ming‐Lung Yu, Yen‐Cheng Chiu, et al. 2024. “Body Weight Increase and Metabolic Derangements after Tenofovir Disoproxil Fumarate Switch to Tenofovir Alafenamide in Patients with Chronic Hepatitis B.” Alimentary Pharmacology & Therapeutics 59 (2): 230–38. doi:10.1111/apt.17765.